Tris Pharma, an emerging specialty pharmaceutical company, has received the US patent for its core technology, OralXR+ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes.

“This patent grant further validates Tris’ breakthrough in commercializing modified release formulation involving unique dosage forms such as a 24-hour ER liquid suspension. The patent covers our unique, high tensile, aqueous coating compositions and combined with our patent-pending/trade-secret manufacturing process and special design apparatus provides for an efficient and scalable manufacturing capabilities. This has resulted in launch of several new, first-in-the-category products that were heretofore not capable of being developed,” said Ketan Mehta, president and CEO of Tris Pharma.

While the benefits of modified release are well understood, these benefits were largely limited to patients who can swallow traditional solid dosage forms. The OralXR+ technology bridges the gap for patients who have difficulty swallowing “pills” and thereby helps extend the market for modified release products. Tris is working with multiple pharma partners to develop products based on this patented technology in the areas of CNS, respiratory, pain, cardiovascular, and OTC cough/cold.

Tris Pharma is focused on the research and development of drug delivery technologies based products.